The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Whole Tumor Antigen Vaccines: Where Are We?
Open accessAbstract
With its vast amount of uncharacterized and characterized T cell epitopes available for activating CD4+ T helper and CD8+ cytotoxic lymphocytes simultaneously, whole tumor antigen represents an attractive alternative source of antigens as compared to tumor-derived peptides and full-length recombinant tumor proteins for dendritic cell (DC)-based immunotherapy. Unlike defined tumor-derived peptides and proteins, whole tumor lysate therapy is applicable to all patients regardless of their HLA type. DCs are essentially the master regulators of immune response, and are the most potent antigen-presenting cell population for priming and activating naïve T cells to target tumors. Because of these unique properties, numerous DC-based immunotherapies have been initiated in the clinics. In this review, we describe the different types of whole tumor antigens that we could use to pulse DCs ex vivo and in vivo. We also discuss the different routes of delivering whole tumor antigens to DCs in vivo and activating them with toll-like receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“One possible mechanism is via the recognition of HSP [27] and HMBG-1 [28] by scavenger receptor-A and TLR4 on DCs, and another mechanism is through interaction with uric acid which is the natural end product of the purine metabolic pathway of degraded cellular RNAs and DNAs [29,30].”
BackgroundGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Molecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
A receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S., & Bhardwaj, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.423 · Cited by 1,358
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Malignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., & Li, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.1 · Cited by 805
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011624 · Cited by 774
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Gastpar, R., Gehrmann, M., Bausero, M. A., Asea, A., Gross, C., Schroeder, J. A., & Multhoff, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3804 · Cited by 695
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 693
Induction of myeloid‐derived suppressor cells by tumor exosomes
Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z., Wang, J., Cheng, Z., Shah, S. V., Wang, G., Zhang, L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24249 · Cited by 598
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
The extracellular release of HMGB1 during apoptotic cell death
Bell, C. W., Jiang, W., Reich, C. F., & Pisetsky, D. S. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00616.2005 · Cited by 538
Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Clayton, A., Mitchell, J. P., Court, J., Mason, M. D., & Tabi, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3456 · Cited by 520
Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging
Fagnoni, F. F., Vescovini, R., Passeri, G., Bologna, G., Pedrazzoni, M., Lavagetto, G., Casti, A., Franceschi, C., Passeri, M., & Sansoni, P. (2000) · Blood · doi:10.1182/blood.v95.9.2860.009k35_2860_2868 · Cited by 518
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
Fields, R. C., Shimizu, K., & Mulé, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9482 · Cited by 454
Cell surface tumor endothelial markers are conserved in mice and humans.
Carson-Walter, E. B., Watkins, D. N., Nanda, A., Vogelstein, B., Kinzler, K. W., & Croix, B. S. (2001) · PubMed · Cited by 451
Vega, V. L., Rodríguez-Silva, M., Frey, T., Gehrmann, M., Diaz, J. C., Steinem, C., Multhoff, G., Arispe, N., & De Maio, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.4299 · Cited by 449
Klibi, J., Niki, T., Riedel, A., Pioche-Durieu, C., Souquere, S., Rubinstein, E., Le Moulec, S., Guigay, J., Hirashima, M., Guemira, F., et al. (2009) · Blood · doi:10.1182/blood-2008-02-142596 · Cited by 436
Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance
STEINMAN, R. M., HAWIGER, D., LIU, K., BONIFAZ, L., BONNYAY, D., MAHNKE, K., IYODA, T., RAVETCH, J., DHODAPKAR, M., INABA, K., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06029.x · Cited by 426
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, Y., Kimberly, R., Grizzle, W. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6867 · Cited by 425
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Su, Z. Z., Dannull, J., Heiser, A., Yancey, D. R., Pruitt, S. K., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2003) · PubMed · Cited by 366
Development of Dendritic-Cell Lineages
Wu, L., & Liu, Y.-J. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.006 · Cited by 343
Mears, R., Craven, R. A., Hanrahan, S., Totty, N., Upton, C., Young, S. L., Patel, P., Selby, P. J., & Banks, R. E. (2004) · PROTEOMICS · doi:10.1002/pmic.200400876 · Cited by 335
Rovere, P., Peri, G., Fazzini, F., Bottazzi, B., Doni, A., Bondanza, A., Zimmermann, V. S., Garlanda, C., Fascio, U., Sabbadini, M. G., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4300 · Cited by 327
Prokopowicz, Z. M., Arce, F., Biedron, R., Chiang, C. L.-L., Ciszek, M., Katz, D. R., Nowakowska, M., Zapotoczny, S., Marcinkiewicz, J., & Chain, B. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902606 · Cited by 325
Self-citationSavarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M.-E., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 323
Vik-Mo, E. O., Nyakas, M., Mikkelsen, B. V., Moe, M. C., Due-Tønnesen, P., Suso, E. M. I., Sæbøe-Larssen, S., Sandberg, C., Brinchmann, J. E., Helseth, E., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1453-3 · Cited by 315
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T. W., Balog, J., Pfaff, C., Bagiella, E., Heitjan, D. F., Fine, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.958 · Cited by 311
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309 · cited 2×
“F10 cells and of C57BL/6 wild-type mouse cells [71,72].”
BackgroundHerr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., & Oettgen, H. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1404 · Cited by 300
Chiang, C. L.-L., Benencia, F., & Coukos, G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.02.004 · Cited by 247
Self-citationChen, T., Guo, J., Han, C., Yang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1449 · Cited by 236
Small, E. J., Sacks, N., Nemunaitis, J., Urba, W. J., Dula, E., Centeno, A. S., Nelson, W. G., Ando, D., Howard, C., Borellini, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2937 · Cited by 235
Heemskerk, B., Kvistborg, P., & Schumacher, T. N. M. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 227
Chiang, C. L.-L., Kandalaft, L. E., Tanyi, J., Hagemann, A. R., Motz, G. T., Svoronos, N., Montone, K., Mantia-Smaldone, G. M., Smith, L., Nisenbaum, H. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1185 · Cited by 218
Self-citationYamaguchi, Y., Tsumura, H., Miwa, M., & Inaba, K. (1997) · STEM CELLS · doi:10.1002/stem.150144 · Cited by 215
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Kyte, J. A., Mu, L., Aamdal, S., Kvalheim, G., Dueland, S., Hauser, M., Gullestad, H. P., Ryder, T., Lislerud, K., Hammerstad, H., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700961 · Cited by 212
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1
Carpentier, A., Laigle-Donadey, F., Zohar, S., Capelle, L., Behin, A., Tibi, A., Martin-Duverneuil, N., Sanson, M., Lacomblez, L., Taillibert, S., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000475 · Cited by 212
TEM8 Interacts with the Cleaved C5 Domain of Collagen α3(VI)
Nanda, A., Carson-Walter, E. B., Seaman, S., Barber, T. D., Stampfl, J., Singh, S., Vogelstein, B., Kinzler, K. W., & St. Croix, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2408 · Cited by 211
Hepatitis B vaccines: WHO position paper—Recommendations
(2010) · Vaccine · doi:10.1016/j.vaccine.2009.10.110 · Cited by 202
Complexity of dendritic cell subsets and their function in the host immune system
Kushwah, R., & Hu, J. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03457.x · Cited by 199
Scheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425656 · Cited by 199
Dai, S., Wan, T., Wang, B., Zhou, X., Xiu, F., Chen, T., Wu, Y., & Cao, X. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0810 · Cited by 199
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., Lifshitz, S., Magee, M., Oh, J., Mill, S. W., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.269 · Cited by 198
Dendritic cells resurrect antigens from dead cells
Larsson, M., Fonteneau, J. F., & Bhardwaj, N. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01860-9 · Cited by 192
Tumor stroma as targets for cancer therapy
Zhang, J., & Liu, J. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.003 · Cited by 187
Albers, R., van der Wielen, R. P. J., Brink, E. J., Hendriks, H. F. J., Dorovska-Taran, V. N., & Mohede, I. C. M. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601585 · Cited by 181
Nemunaitis, J., Jahan, T., Ross, H., Sterman, D., Richards, D., Fox, B., Jablons, D., Aimi, J., Lin, A., & Hege, K. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700922 · Cited by 180
Derhovanessian, E., Solana, R., Larbi, A., & Pawelec, G. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-11 · Cited by 169 · cited 1×
“Nevertheless, most of the subjects who are enrolled in cancer clinical trials are elderly patients who have significantly compromised immune systems specifically when immunosenescence sets in (reviewed in [99]).”
BackgroundCarbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.158 · Cited by 169
Antigens for cancer immunotherapy
Neller, M. A., López, J. A., & Schmidt, C. W. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.09.006 · Cited by 167
Gribben, J. G., Ryan, D. P., Boyajian, R., Urban, R. G., Hedley, M. L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
Frey, B., Rubner, Y., Kulzer, L., Werthmöller, N., Weiss, E., Fietkau, R., & Gaipl, U. S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1474-y · Cited by 162
Huber, M. A., Schubert, R. D., Peter, R. U., Kraut, N., Park, J. E., Rettig, W. J., & Garin-Chesa, P. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12035.x · Cited by 162
Correlations between membrane viscosity, serum cholesterol, lymphocyte activation and aging in man
Rivnay, B., Bergman, S., Shinitzky, M., & Globerson, A. (1980) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(80)90088-3 · Cited by 160
Dendritic cell derived-exosomes: biology and clinical implementations
Chaput, N., Flament, C., Viaud, S., Taïeb, J., Roux, S., Spatz, A., André, F., Pecq, J. L., Boussac, M., Garin, J., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0206094 · Cited by 160
Jenne, L., Arrighi, J.-F., Jonuleit, H., Saurat, J. ‐., & Hauser, C. (2000) · PubMed · Cited by 159
Dissection of T-cell Antigen Specificity in Human Melanoma
Andersen, R. S., Thrue, C. A., Junker, N., Lyngaa, R., Donia, M., Ellebæk, E., Svane, I. M., Schumacher, T. N., thor Straten, P., & Hadrup, S. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2614 · Cited by 158
Ostberg, J. R., Dayanç, B. E., Yuan, M., Oflazoglu, E., & Repasky, E. A. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1106699 · Cited by 138
López, M. N., Pereda, C., Segal, G., Muñoz, L., Aguilera, R., González, F. E., Escobar, A. F., Ginesta, A., Reyes, D., González, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0794 · Cited by 136
Soluble plasma HLA peptidome as a potential source for cancer biomarkers
Bassani‐Sternberg, M., Barnea, E., Beer, I., Avivi, I. M., Katz, T., & Admon, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008501107 · Cited by 135
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer
Simons, J. W., Carducci, M. A., Mikhak, B., Lim, M. K., Biedrzycki, B. A., Borellini, F., Clift, S., Hege, K. M., Ando, D. G., Piantadosi, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0145 · Cited by 134
Larbi, A., Douziech, N., Dupuis, G., Khalil, A., Pelletier, H., Guérard, K., & Fülöp, T. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0703319 · Cited by 130
Uric Acid Promotes Tumor Immune Rejection
Hu, D., Moore, A. M., Thomsen, L. L., & Brindle, K. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1586 · Cited by 130
Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines
Chiang, C. L.-L., Kandalaft, L. E., & Coukos, G. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.572210 · Cited by 119
Self-citationMarko, M. G., Ahmed, T., Bunnell, S. C., Wu, D., Chung, H., Huber, B. T., & Meydani, S. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1443 · Cited by 118
Roth, J., Dittmer, D. P., Réa, D., Tartaglia, J., Paoletti, E., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4781 · Cited by 118
Merogi, A. J., Marrogi, A. J., Ramesh, R., Robinson, W. R., Fermin, C. D., & Freeman, S. M. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90131-3 · Cited by 117
Huang, Y., Wang, S., & Kelly, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3184 · Cited by 117
GM-CSF Gene-Transduced Tumor Vaccines
Eager, R. M., & Nemunaitis, J. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.012 · Cited by 108
IL-7 Gene Therapy in Aging Restores Early Thymopoiesis without Reversing Involution
Phillips, J. A., Brondstetter, T. I., English, C. A., Lee, H. E., Virts, E. L., & Thoman, M. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4867 · Cited by 104
Baruah, P., Propato, A., Dumitriu, I. E., Rovere, P. Q., Russo, V. E. A., Fontana, R., Accapezzato, D., Peri, G., Mantovani, A., Barnaba, V., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1112 · Cited by 102
Hyperthermia Enhances CTL Cross-Priming
Shi, H., Cao, T., Connolly, J. E., Monnet, L., Bennett, L. B., Chapel‐Fernandes, S., Bagnis, C., Mannoni, P., Davoust, J. M., Palucka, A. K., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2134 · Cited by 101
Kandalaft, L. E., Motz, G. T., Busch, J. I., & Coukos, G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_95 · Cited by 99
Self-citationIntradermal immunization improves protective efficacy of a novel TB vaccine candidate
Baldwin, S. L., Bertholet, S., Kahn, M., Zharkikh, I. L., Ireton, G. C., Vedvick, T. S., Reed, S. G., & Coler, R. N. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.018 · Cited by 98
Borrello, I., Levitsky, H. I., Stock, W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205278 · Cited by 98
Iwasa, S., Okada, K., Chen, W., Jin, X., Yamane, T., Ooi, A., & Mitsumata, M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.030 · Cited by 97
INTRADERMAL HEPATITIS B VIRUS VACCINE: IMMUNOGENICITY AND SIDE-EFFECTS IN ADULTS
Miller, K., Mulligan, M., Gibbs, R., Nutman, T., & Francis, D. P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90800-0 · Cited by 89
Tani, K., Azuma, M., Nakazaki, Y., Oyaizu, N., Hase, H., Ohata, J., TAKAHASHI, K. G., Oiwa‐Monna, M., Hanazawa, K., Wakumoto, Y., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.001 · Cited by 86
Fishman, M., Hunter, T. B., Soliman, H. H., Thompson, P. L., Dunn, M. W., Smilee, R. C., Farmelo, M. J., Noyes, D. R., Mahany, J. J., Lee, J., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ba792 · Cited by 79
Mueller, M., Reichardt, W., Koerner, J., & Groettrup, M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.015 · Cited by 78
Deciphering the Message Broadcast by Tumor-Infiltrating Dendritic Cells
Karthaus, N., Torensma, R., & Tel, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.012 · Cited by 78
Wu, A., Oh, S., Gharagozlou, S., Vedi, R. N., Ericson, K., Low, W. C., Chen, W., & Ohlfest, J. R. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318155a0f6 · Cited by 75
The Expression of a Type II Transmembrane Serine Protease (Seprase) in Human Gastric Carcinoma
Mori, Y., Kono, K., Matsumoto, Y., et al. (2004) · Oncology · doi:10.1159/000082926 · Cited by 74
Benencia, F., Courreges, M. C., & Coukos, G. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-21 · Cited by 73
Self-citationBaars, A., Claessen, A. M. E., van den Eertwegh, A. J. M., Gall, H. E., Stam, A. G. M., Meijer, S., Giaccone, G., Meijer, C. J. L. M., Scheper, R. J., Wagstaff, J., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008363601515 · Cited by 69
Adaptive Vaccination Strategies to Mitigate Pandemic Influenza: Mexico as a Case Study
Chowell, G., Viboud, C. G., Wang, X., Bertozzi, S., & Miller, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008164 · Cited by 69
Iwasa, S., Jin, X., Okada, K., Mitsumata, M., & Ooi, A. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00315-x · Cited by 68
Chiang, C. L.-L., Ledermann, J. A., Rad, A. N., Katz, D. R., & Chain, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0127-9 · Cited by 64
Self-citationChiang, C. L.-L., Ledermann, J. A., Aitkens, E., Benjamin, E. O., Katz, D. R., & Chain, B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4899 · Cited by 60
Self-citationAutologous, hapten-modified vaccine as a treatment for human cancers.
Berd, D., Kairys, J. C., Dunton, C. J., Mastrangelo, M. J., Sato, T., & Maguire, H. (1998) · PubMed · Cited by 57
RNA Vaccines in Cancer Treatment
Bringmann, A., Held, S. A. E., Heine, A., & Brossart, P. (2010) · BioMed Research International · doi:10.1155/2010/623687 · Cited by 57
Kreiter, S., Konrad, T., Sester, M., Huber, C., Türeci, Ö., & Şahin, U. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0302-7 · Cited by 55
NIRMAL, S. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00293-4 · Cited by 54
Sandberg, J. K., Grufman, P., Wolpert, E. Z., Franksson, L., Chambers, B. J., & Kärre, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3163 · Cited by 54
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma
Powell, A., Creaney, J., Broomfield, S., van Bruggen, I., & Robinson, B. W. S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.007 · Cited by 49
Gross, B., Wongrakpanich, A., Francis, M. B., Salem, A. K., & Norian, L. A. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9662-z · Cited by 49
Wang, X., Arnouk, H., Chen, X., Kazim, L., Repasky, E. A., & Subjeck, J. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1543 · Cited by 47
Carralot, J., Weide, B., Schoor, O., Probst, J., Scheel, B., Teufel, R., Hoerr, I., Garbe, C., Rammensee, H., & Pascolo, S. (2005) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-3-6 · Cited by 44
Rahma, O. E., Ashtar, E., Ibrahim, R. A., Toubaji, A., Gause, B. L., Herrin, V. E., Linehan, W. M., Steinberg, S. M., Grollman, F., Grimes, G. J., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-8 · Cited by 41
Development of combined vaccines for rabies and immunocontraception
Wu, X., Franka, R., Svoboda, P., Pohl, J., & Rupprecht, C. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.025 · Cited by 39
Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics
Kuhn, A. N., Diken, M., Kreiter, S., Vallazza, B., Türeci, Ö., & Sahin, U. (2011) · RNA Biology · doi:10.4161/rna.8.1.13767 · Cited by 39
Targets of Protective Tumor Immunity
Dranoff, G. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04938.x · Cited by 36
Nemunaitis, J., & Nemunaitis, J. J. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.027 · Cited by 21
Tissue-based immune monitoring I
Hagemann, A. R., Cadungog, M. G., Hagemann, I. S., Hammond, R., Adams, S. F., Chu, C., Rubin, S. C., Zhang, L., Addya, K., Birrer, M. J., et al. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16951 · Cited by 11
Self-citation
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 401
A melanin-mediated cancer immunotherapy patch
Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5692 · Cited by 381
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Metadata
- Authors
- Chiang, C., Coukos, G., & Kandalaft, L.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2015-04-23
- Volume
- 3
- Issue
- 2
- Pages
- 344-372
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W2061662618
- Cited by
- 269
- References
- 122
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.